136 related articles for article (PubMed ID: 16730121)
1. Effect of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, on motor performance in mice.
Miyamoto M
Neurosci Lett; 2006 Jul; 402(3):201-4. PubMed ID: 16730121
[TBL] [Abstract][Full Text] [Related]
2. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.
Kato K; Hirai K; Nishiyama K; Uchikawa O; Fukatsu K; Ohkawa S; Kawamata Y; Hinuma S; Miyamoto M
Neuropharmacology; 2005 Feb; 48(2):301-10. PubMed ID: 15695169
[TBL] [Abstract][Full Text] [Related]
3. Melatonin receptor agonist ramelteon activates the extracellular signal-regulated kinase 1/2 in mouse cerebellar granule cells.
Imbesi M; Uz T; Manev H
Neuroscience; 2008 Sep; 155(4):1160-4. PubMed ID: 18664376
[TBL] [Abstract][Full Text] [Related]
4. Molecular cloning and pharmacological characterization of monkey MT1 and MT2 melatonin receptors showing high affinity for the agonist ramelteon.
Nishiyama K; Shintani Y; Hirai K; Yoshikubo S
J Pharmacol Exp Ther; 2009 Sep; 330(3):855-63. PubMed ID: 19556449
[TBL] [Abstract][Full Text] [Related]
5. Ramelteon, a selective MT1/MT2 receptor agonist, suppresses the proliferation and invasiveness of endometrial cancer cells.
Osanai K; Kobayashi Y; Otsu M; Izawa T; Sakai K; Iwashita M
Hum Cell; 2017 Jul; 30(3):209-215. PubMed ID: 28382516
[TBL] [Abstract][Full Text] [Related]
6. Ramelteon: TAK 375.
Drugs R D; 2005; 6(3):186-8. PubMed ID: 15869323
[TBL] [Abstract][Full Text] [Related]
7. A Case of Unilateral Hypnic Headache: Rapid Response to Ramelteon, a Selective Melatonin MT1/MT2 Receptor Agonist.
Arai M
Headache; 2015; 55(7):1010-1. PubMed ID: 26121162
[No Abstract] [Full Text] [Related]
8. Pharmacological characterization of M-II, the major human metabolite of ramelteon.
Nishiyama K; Nishikawa H; Kato K; Miyamoto M; Tsukamoto T; Hirai K
Pharmacology; 2014; 93(3-4):197-201. PubMed ID: 24923230
[TBL] [Abstract][Full Text] [Related]
9. [A novel therapeutic drug: ramelteon].
Miyamoto M
Nihon Rinsho; 2009 Aug; 67(8):1595-600. PubMed ID: 19768947
[TBL] [Abstract][Full Text] [Related]
10. Melatonin receptors mediate improvements of survival in a model of polymicrobial sepsis.
Fink T; Glas M; Wolf A; Kleber A; Reus E; Wolff M; Kiefer D; Wolf B; Rensing H; Volk T; Mathes AM
Crit Care Med; 2014 Jan; 42(1):e22-31. PubMed ID: 24145838
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.
Miyamoto M
CNS Neurosci Ther; 2009; 15(1):32-51. PubMed ID: 19228178
[TBL] [Abstract][Full Text] [Related]
12. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2.
Greenblatt DJ; Harmatz JS; Karim A
J Clin Pharmacol; 2007 Apr; 47(4):485-96. PubMed ID: 17389558
[TBL] [Abstract][Full Text] [Related]
13. Fresh from the pipeline: Ramelteon.
Buysse D; Bate G; Kirkpatrick P
Nat Rev Drug Discov; 2005 Nov; 4(11):881-2. PubMed ID: 16299918
[No Abstract] [Full Text] [Related]
14. Melatonin receptor activation provides cerebral protection after traumatic brain injury by mitigating oxidative stress and inflammation via the Nrf2 signaling pathway.
Wang J; Jiang C; Zhang K; Lan X; Chen X; Zang W; Wang Z; Guan F; Zhu C; Yang X; Lu H; Wang J
Free Radic Biol Med; 2019 Feb; 131():345-355. PubMed ID: 30553970
[TBL] [Abstract][Full Text] [Related]
15. A Cluster Headache Responsive to Ramelteon, a Selective Melatonin MT1/MT2 Receptor Agonist.
Imai N
Intern Med; 2016; 55(17):2483-5. PubMed ID: 27580554
[TBL] [Abstract][Full Text] [Related]
16. Stimulatory effects of a melatonin receptor agonist, ramelteon, on BDNF in mouse cerebellar granule cells.
Imbesi M; Uz T; Dzitoyeva S; Manev H
Neurosci Lett; 2008 Jul; 439(1):34-6. PubMed ID: 18501512
[TBL] [Abstract][Full Text] [Related]
17. Acute sleep-promoting action of the melatonin agonist, ramelteon, in the rat.
Fisher SP; Davidson K; Kulla A; Sugden D
J Pineal Res; 2008 Sep; 45(2):125-32. PubMed ID: 18298466
[TBL] [Abstract][Full Text] [Related]
18. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment.
Roth T; Stubbs C; Walsh JK
Sleep; 2005 Mar; 28(3):303-7. PubMed ID: 16173650
[TBL] [Abstract][Full Text] [Related]
19. Melatonin MT
López-Canul M; Min SH; Posa L; De Gregorio D; Bedini A; Spadoni G; Gobbi G; Comai S
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31108968
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune hepatitis in association with ramelteon.
Fourman LT; Robert Meyer B
J Clin Gastroenterol; 2013 Aug; 47(7):651-4. PubMed ID: 23632362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
